Affordable Access

deepdyve-link
Publisher Website

Renal denervation: unde venis et quo vadis?

Authors
  • Nähle, C P
  • Düsing, R
  • Schild, H
Type
Published Article
Journal
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
Publication Date
Apr 01, 2015
Volume
187
Issue
4
Pages
237–247
Identifiers
DOI: 10.1055/s-0034-1385526
PMID: 25629384
Source
Medline
License
Unknown

Abstract

The indication for renal denervation should be assessed in an interdisciplinary fashion and according to current guidelines with a special focus on ruling out secondary causes for arterial hypertension. 5 - 10 % of patients with hypertension suffer from refractory hypertension, but only about 1 % of patients meet the criteria for a renal denervation. Renal denervation leads to a significant decrease in office blood pressure; however, the impact on 24-hour blood pressure measurements remains unclear. In the first randomized controlled trial on renal denervation with a control group undergoing a sham procedure, blood pressure reduction failed to reach the anticipated level of superiority over best medical treatment. Periprocedural complications are rare, but long-term safety can currently not be appraised due to the limited data available.

Report this publication

Statistics

Seen <100 times